Nasdaq:US$15.86 (+1.02) | HKEX:HK$25.02 (+1.62) | AIM:£2.35 (+0.2)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification